| BRCA2 Mutation19 |
|---|
| Olaparib | Castration-Resistant Prostate Carcinoma | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID8842In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous … (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| 〃 | Malignant Breast Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID5831Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients we… (full text at CIViC) PMID 28792849 · 2017 · Open in CIViC | civic |
| 〃 | Malignant NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1371In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only o… (full text at CIViC) PMID 19553641 · Fong et al., 2009 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID7276In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1773In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations. Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective r… (full text at CIViC) PMID 21862407 · Gelmon et al., 2011 · Open in CIViC | civic |
| Cediranib + OlaparibCombination | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID167846 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy. Median PFS was increased in combination therapy (… (full text at CIViC) PMID 25218906 · Liu et al., 2014 · Open in CIViC | civic |
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11137Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11139Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID2868A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID6343A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| Iniparib | Malignant Pancreatic Neoplasm | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID5936Patient with germline BRCA2 mutation underwent resection of pancreatic cancer.
Around three years later, tumor recurrence was detected by MRI and PET-CT confirmed it. She was treated with gemcitabine … (full text at CIViC) PMID 21508395 · Fogelman et al., 2011 · Open in CIViC | civic |
| Olaparib | Malignant Pancreatic Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID5913Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation.
In total of patients with BRCA1/2 mutation , all but … (full text at CIViC) PMID 25366685 · Kaufman et al., 2015 · Open in CIViC | civic |
| Platinum Compound | Malignant Pancreatic Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID5916Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively.
In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=2… (full text at CIViC) PMID 25072261 · Golan et al., 2014 · Open in CIViC | civic |
| Veliparib | Malignant Pancreatic Neoplasm | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID5935Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy… (full text at CIViC) PMID 29223478 · Lowery et al., 2018 · Open in CIViC | civic |
| Cisplatin + Gemcitabine + VeliparibCombination | Malignant Pancreatic Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID5933In Phase I study for pancreatic cancer patients
GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of 77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-p… (full text at CIViC) PMID 29338080 · O'Reilly et al., 2018 · Open in CIViC | civic |
| Platinum Compound | Ovarian Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1530In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC | civic |
| 〃 | Ovarian Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1532In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC | civic |
| Carboplatin + CisplatinSubstitutes | Triple-Negative Breast CarcinomaALIAS | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1685In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC) PMID 25847936 · Isakoff et al., 2015 · Open in CIViC | civic |
| Olaparib | Triple-Negative Breast CarcinomaALIAS | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID1776In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative. Regardless of BRCA status, none showed objective response when treated with olaparib. PMID 21862407 · Gelmon et al., 2011 · Open in CIViC | civic |